Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability of a Four Weeks Treatment With Aggrenox® Modified Release Capsules b.i.d, Compared to Reduced Dose During the First Two Weeks of Treatment in a Double-Blind, Randomized Controlled Parallel Group Comparison Trial Among Taiwanese Patients With Previous TIAs or Ischemic Stroke

NCT00274586 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00274586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00274586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability of a Four Weeks Treatment With Aggrenox® Modified Release Capsules b.i.d, Compared to Reduced Dose During the First Two Weeks of Treatment in a Double-Blind, Randomized Controlled Parallel Group Comparison Trial Among Taiwanese Patients With Previous TIAs or Ischemic Stroke
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2002
Completion date
April 30, 2003
Enrollment
100
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebrovascular accident